查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011521

心臟衰竭治療市場：2026-2032年全球市場預測（按藥物類別、心臟衰竭類型、給藥途徑、最終用戶和分銷管道分類）

Heart Failure Therapeutics Market by Drug Class, Heart Failure Type, Mode Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，心臟衰竭治療市場價值將達到 291 億美元，到 2026 年將成長至 316.9 億美元，到 2032 年將達到 602.3 億美元，複合年成長率為 10.94%。

主要市場統計數據
基準年 2025 291億美元
預計年份：2026年 316.9億美元
預測年份 2032 602.3億美元
複合年成長率 (%) 10.94%

對現代心臟衰竭藥物進行簡明背景概述，重點在於臨床重點、護理路徑以及相關人員的操作決策因素。

心臟衰竭的治療正處於臨床緊迫性、不斷發展的分子科學和不斷變化的醫療服務模式的交匯點。本執行摘要整合了當前臨床醫生、保險公司、行業領導者和政策制定者所面臨的情況，重點關注影響患者預後的最關鍵治療分類和治療路徑。引言部分將近期治療進展置於不斷更新的臨床指南和日益成長的慢性病管理關注度的背景下，使後續分析圍繞實際應用而非抽象預測。

對藥物創新、精細表現型分析和不斷發展的醫療保健服務模式如何共同重塑治療策略和獲取途徑進行詳細分析。

心臟衰竭的治療格局正在經歷一場變革，其驅動力包括創新、不斷更新的指南以及醫療服務體系的重塑。藥理學的進步拓展了臨床醫生的治療手段，使其不再局限於傳統的血流動力學療法，而是涵蓋了針對代謝、發炎以及腎臟和心臟軸的藥物。因此，諸如ACE抑制劑、ARB、 BETA阻斷劑、利尿劑、鹽皮質激素受體拮抗劑（MRA）和SGLT2抑制劑等傳統藥物類別正在被重新評估，並納入更精細的治療方案中，而聯合用藥策略和給藥順序的重要性也日益凸顯。

對近期關稅趨勢對供應鏈的影響及其對採購、分銷和醫療保健系統運營的影響進行全面評估。

美國近期關稅政策的變化對心臟衰竭藥物產業的製造商、經銷商和下游醫療服務提供者產生了多方面的影響。關稅的變化會影響整個供應鏈的成本結構，包括原料藥、成品以及用於監測和給藥的醫療設備相關產品的到貨成本。這些壓力可能導致與醫院系統和藥房網路的合約關係發生變化，進而促使公共和私人支付方重新評估其籌資策略。

透過利用整合藥物類別、表現型差異、給藥途徑、醫療保健環境和流通結構的多維細分見解，我們支持有針對性的策略制定。

藥物細分提供了必要的分析框架，可以將細微的治療差異轉化為可操作的策略。按藥物類別分類，治療方法選擇差異顯著。 ACE抑制劑和ARB類藥物仍是神經激素調節的基礎； BETA阻斷劑抑制交感神經過度活躍；利尿劑用於管理有症狀患者的體液平衡；鹽皮質激素受體拮抗劑（MRA）有助於拮抗劑抑制鹽皮質激素；SGLT2抑制劑則具有超越傳統類別界限的有益代謝和腎臟/心臟效應。這些類別層面的差異直接影響臨床路徑和商業性定位。

區域趨勢和醫療保健系統特徵決定了世界各地市場在治療方法引入、報銷途徑和醫療保健服務方面的差異。

區域趨勢對全球心臟衰竭治療領域的治療方法採納、報銷和實施方式有著深遠的影響。在美洲，支付方結構、整合的醫療網路以及高密度的專科醫療中心促進了通訊協定的快速推廣，並為專科通路和醫院主導的治療啟動鋪平了道路。私人和公共支付方模式的多樣性也影響報銷談判和處方藥清單，並對治療價值的體現方式產生連鎖反應。

為整合科學差異化、證據產生和經銷夥伴以支持治療方法。

企業策略日益取決於其如何有效地將科學差異化與貫穿整個醫療服務鏈的實際應用相結合。主要企業和商業機構正將研發、證據產生和生命週期管理重點放在能夠滿足射血分數正常和降低患者群體未滿足醫療需求的化合物和聯合治療上。策略重點包括：在硬終點上證明療效、闡明合併症患者群體的安全性特徵，以及產生可操作的證據以支持在常規臨床實踐中推廣應用。

開發人員、付款方和醫療保健提供者可以採取哪些行動來增強臨床和商業途徑中的可及性、證據完整性和供應韌性。

行業領導者可以採取切實措施，提高心臟衰竭治療的可近性、臨床療效和商業性韌性。首先，應使臨床開發和核准後證據項目與支付方和醫療保健系統關注的可操作終點（例如避免住院和功能狀態）保持一致，同時確保試驗能夠涵蓋與保守治療和低射血分數組相關的各種患者表現型。其次，應制定能夠銜接住院和門診環境的上市和商業化計劃，並與醫院藥房團隊、診所網路和居家照護機構合作，制定清晰的治療啟動和過渡通訊協定。

透過採用穩健的混合方法研究設計，結合臨床醫生的回饋、有針對性的文獻整合和情境分析，我們確保了可操作性和有效性的研究結果。

本研究採用混合方法，旨在產生嚴謹且可操作的見解，以彌合臨床細微差別與商業性現實之間的差距。主要定性資料包括對醫院系統、診所和居家照護機構的活躍循環系統、心臟衰竭專科護理師、藥屋主任和採購經理進行的結構化訪談，以收集第一線觀點對治療方法選擇、實施流程和用藥依從性挑戰的看法。這些一線見解輔以基於同行評審的臨床文獻、監管指南和公開的醫療保健系統報告的二手研究，從而將臨床療效、安全性和指南演變置於更廣闊的背景中進行分析。

對臨床、營運和區域主題進行綜合分析，為將治療進展轉化為永續的患者獲益提供切實可行的途徑。

總之，目前心臟衰竭的治療現況呈現顯著的臨床進展和操作複雜性。治療方案的差異化已不再局限於傳統的血流動力學目標，而是擴展到包括那些能夠改善腎功能和代謝的藥物，這就需要更加精細的臨床決策過程，該過程需綜合考慮表現型、疾病嚴重程度和合併症。這些科學進步與醫療服務模式的變革交織，診所、醫院和居家照護在治療啟動、劑量調整和長期管理中各自扮演著不同的角色。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章心臟衰竭治療市場：依藥物類別分類

  • ACE抑制劑
  • ARB
  • BETA阻斷劑
  • 利尿劑
  • MRA
  • SGLT2抑制劑

第9章：以心臟衰竭類型分類的心臟衰竭治療市場

  • 正常射血分數
    • 急性
    • 慢性的
  • 射血分數降低型
    • 急性
    • 慢性的

第10章：依給藥途徑分類的心臟衰竭治療市場

  • 靜脈注射
  • 口服

第11章心臟衰竭治療市場：依最終用戶分類

  • 診所
  • 居家照護設施
  • 醫院

第12章心臟衰竭藥物市場：依分銷管道分類

  • 離線
    • 醫院藥房
    • 零售藥房
  • 線上

第13章心臟衰竭治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章心臟衰竭治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章心臟衰竭治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國心臟衰竭藥物市場

第17章：中國心臟衰竭藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Abiomed, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • Cytokinetics, Inc.
  • Edwards Lifesciences Corporation
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Les Laboratoires Servier
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-430D42AA0D2E

The Heart Failure Therapeutics Market was valued at USD 29.10 billion in 2025 and is projected to grow to USD 31.69 billion in 2026, with a CAGR of 10.94%, reaching USD 60.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 29.10 billion
Estimated Year [2026] USD 31.69 billion
Forecast Year [2032] USD 60.23 billion
CAGR (%) 10.94%

Concise contextual framing of contemporary heart failure therapeutics highlighting clinical priorities, care pathways, and operational decision levers for stakeholders

Heart failure therapeutics occupy a pivotal intersection of clinical urgency, evolving molecular science, and shifting care delivery models. This executive summary synthesizes the contemporary landscape for clinicians, payers, industry leaders, and policy makers, emphasizing the therapeutic classes and care pathways that matter most in shaping patient outcomes. The introduction situates recent therapeutic advances against a backdrop of changing clinical guidelines and heightened attention to chronic disease management, framing the rest of the analysis around practical implications rather than abstract projections.

The discussion foregrounds how incremental innovations across established drug classes, alongside newer agents and adjunctive care strategies, are redefining treatment algorithms. It emphasizes the practical considerations that influence adoption in routine care, such as route of administration, acute versus chronic management distinctions, and where care is delivered-clinic, hospital, or home settings. By anchoring the narrative to real-world decision levers, this section prepares the reader for deeper analysis of landscape shifts, tariff impacts, segmentation insights, and regional dynamics that follow.

Throughout, the tone balances clinical nuance and commercial pragmatism. The introduction does not seek to catalog every development but rather to clarify the themes that determine therapeutic value, stakeholder priorities, and the operational adjustments organizations will need to make to capitalize on emerging opportunities in heart failure care.

Detailed analysis of how pharmacologic innovation, refined phenotyping, and evolving care delivery models are jointly reshaping therapeutic strategies and access pathways

The therapeutic landscape for heart failure is undergoing transformative shifts driven by a confluence of innovation, guideline evolution, and care delivery redesign. Advances in pharmacology are broadening the clinician's toolkit beyond traditional modulators of hemodynamics to include agents that target metabolic, inflammatory, and renal-cardiac axes. As a result, established categories such as ACE inhibitors, ARBs, beta blockers, diuretics, MRAs, and SGLT2 inhibitors are being re-evaluated within more finely stratified treatment pathways, while combination strategies and sequencing considerations gain prominence.

Concurrently, diagnostic refinements and a deeper understanding of phenotype heterogeneity have sharpened focus on preserved versus reduced ejection fraction subtypes, and on acute as distinct from chronic management. These clinical delineations affect therapeutic selection, monitoring intensity, and expected outcomes. Mode-of-administration preferences are also shifting, as oral chronic regimens interact with intermittent or acute intravenous interventions tied to hospitalization patterns and home-based care expansion.

Operationally, distribution and access channels show parallel transformation. Offline channels anchored in hospital and retail pharmacies remain essential for acute care and specialty dispensing, while online fulfillment and telehealth-enabled prescribing are gaining traction for chronic medication continuity. End-user dynamics-clinics, home care settings, and hospitals-are adapting to new protocols for initiation, titration, and monitoring, reshaping how evidence translates into practice. The cumulative effect is a landscape where therapeutic choice, care setting, and access mechanisms co-evolve rapidly, demanding coordinated strategies across clinical, commercial, and policy domains.

Comprehensive appraisal of recent tariff-driven supply chain effects and their operational consequences for procurement, distribution, and therapeutic access frameworks

Recent tariff developments in the United States have introduced layered implications for manufacturers, distributors, and downstream care providers operating in the heart failure therapeutics space. Tariff changes influence cost structures across the supply chain, affecting the landed cost of active pharmaceutical ingredients, finished dose formulations, and device-adjacent products used in monitoring and administration. These pressures can alter contracting dynamics with hospital systems and pharmacy networks and may prompt re-evaluation of procurement strategies for both public and private payers.

The operational ripple effects extend to channel economics. Hospital pharmacy procurement practices, retail pharmacy stocking decisions, and online distribution agreements are sensitive to input-cost variability created by tariff adjustments. In response, manufacturers may pursue localized sourcing, alternative supplier partnerships, or renegotiated distribution terms to preserve margin and ensure uninterrupted patient access. Similarly, providers under value-based payment arrangements might reassess formularies and therapeutic pathways to manage total cost of care while maintaining clinical standards.

Clinicians and health system leaders will need to balance short-term operational adjustments with long-term resilience measures. This entails closer coordination among supply chain, pharmacy, and clinical leadership, increased scenario planning for potential supply disruptions, and strategic dialogue with payers to preserve access to guideline-recommended therapies. Ultimately, tariff-induced cost pressures act as a catalyst for more integrated procurement and therapeutic stewardship practices across the delivery ecosystem.

Multidimensional segmentation insights that reconcile drug class, phenotype distinctions, administration routes, care settings, and distribution architectures to inform targeted strategies

Segmentation provides the analytical scaffolding needed to translate therapeutic nuance into actionable strategy. When viewed through the lens of drug class differentiation, therapeutic choice varies markedly: ACE inhibitors and ARBs remain foundational for neurohormonal modulation, beta blockers address sympathetic overactivity, diuretics manage fluid balance in symptomatic patients, MRAs contribute to mineralocorticoid antagonism, and SGLT2 inhibitors offer metabolic and renal-cardiac benefits that cross traditional class boundaries. These class-level distinctions directly shape clinical pathways and commercial positioning.

Disaggregating by heart failure type further refines decision-making. Preserved ejection fraction and reduced ejection fraction represent biologically and operationally distinct domains; within each, acute episodes necessitate different initiation, titration, and monitoring strategies compared with chronic maintenance care. Mode of administration introduces an orthogonal axis of differentiation: intravenous therapy dominates the acute, inpatient context, while oral regimens support chronic outpatient management and enable continuity across clinic and home care settings.

End-user segmentation-clinics, home care settings, and hospitals-captures the practical realities of where therapies are initiated and maintained, influencing patient support programs, adherence interventions, and monitoring infrastructure. Distribution channel nuances between offline and online channels, with offline further split into hospital and retail pharmacies, affect time-to-treatment, inventory management, and patient convenience. Together, these intersecting segmentation axes provide a multidimensional view that supports targeted clinical protocols, differentiated commercial strategies, and operational investments in logistics and patient support.

Regional dynamics and health system characteristics that shape therapeutic adoption, reimbursement pathways, and care delivery variations across global markets

Regional dynamics exert a powerful influence on how therapies are adopted, reimbursed, and delivered across the global heart failure landscape. In the Americas, payer structures, integrated delivery networks, and a high concentration of specialist centers shape rapid protocol adoption and create pathways for specialty distribution and hospital-led therapeutics initiation. The breadth of private and public payer models also affects reimbursement negotiations and formulary placements, with implications for how therapeutic value is demonstrated.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks, funding mechanisms, and clinical infrastructure leads to variable uptake patterns. National health systems and regional procurement bodies often prioritize cost-effectiveness and therapeutic outcomes, which drives emphasis on real-world evidence generation and outcomes-based contracting. Differences in diagnostic capacity and access to specialty care can alter the balance between clinic-based initiation and hospital-centered management.

Asia-Pacific presents both large urban centers with advanced tertiary care and vast regions where access is constrained by logistics and infrastructure. This diversity influences the adoption of oral chronic regimens versus reliance on acute inpatient interventions, and it elevates the role of digital health and telemedicine in bridging care gaps. Across all regions, local regulatory nuance, supply-chain robustness, and payer expectations will determine how therapeutic innovations translate into measurable clinical impact.

Strategic corporate priorities and operational playbooks that integrate scientific differentiation, evidence generation, and distribution partnerships to support therapeutic adoption

Company strategies are increasingly defined by how effectively they align scientific differentiation with operational execution across the care continuum. Leading developers and commercial organizations are concentrating R&D, evidence generation, and lifecycle management around compounds and combinations that address unmet needs within preserved and reduced ejection fraction populations. Strategic priorities include demonstrating benefit in hard clinical outcomes, elucidating safety profiles across comorbid populations, and generating pragmatic evidence that supports adoption in routine practice.

On the commercial front, firms are optimizing launch sequencing and channel partnerships to manage the transition between inpatient initiation and outpatient maintenance. Collaboration with hospital systems, specialty pharmacies, and home care providers helps secure pathways for initiation, ensures continuity during post-discharge transitions, and supports adherence programs. Investments in real-world evidence platforms and patient monitoring technologies strengthen value propositions in negotiations with payers and integrated delivery networks.

Operationally, companies are also refining supply chain strategies to mitigate tariff and sourcing risks, enhancing forecasting models tied to clinical utilization patterns, and developing tailored pricing approaches for diverse regional reimbursement landscapes. Partnerships with digital health providers and diagnostics companies are increasingly common, aimed at connecting therapeutic interventions with monitoring and adherence solutions that improve outcomes and support long-term product differentiation.

Practical, prioritized actions for developers, payers, and providers to enhance access, evidence alignment, and supply resilience across clinical and commercial pathways

Industry leaders can take concrete steps to strengthen therapeutic access, clinical outcomes, and commercial resilience in heart failure care. First, align clinical development and post-approval evidence programs with the practical endpoints that matter to payers and health systems, such as hospitalization avoidance and functional status, while ensuring trials capture heterogeneous patient phenotypes relevant to preserved and reduced ejection fraction populations. Second, design launch and commercialization plans that bridge inpatient and outpatient settings, coordinating with hospital pharmacy teams, clinic networks, and home care providers to create clear initiation and handoff protocols.

Additionally, prioritize procurement resilience by diversifying supplier networks and exploring near-shoring options for critical inputs to reduce exposure to tariff volatility. Invest in digital and remote-monitoring tools that support adherence and early detection of decompensation, thereby enhancing clinical value and reducing downstream costs. Engage proactively with payers to develop outcome-based contracting mechanisms that align reimbursement with real-world therapeutic performance.

Finally, strengthen regional strategies by tailoring evidence generation and pricing approaches to local regulatory and reimbursement contexts. Build cross-functional teams that integrate clinical, regulatory, reimbursement, and supply chain expertise to execute complex market entry and lifecycle initiatives. These actions will help leaders convert therapeutic promise into sustained clinical and commercial impact while preserving access for patients across diverse care settings.

Robust mixed-methods research design combining frontline clinician input, targeted literature synthesis, and scenario analysis to ensure actionable and defensible insights

This research employs a mixed-methods approach designed to produce rigorous, actionable insights that bridge clinical nuance and commercial realities. Primary qualitative inputs include structured interviews with practicing cardiologists, heart failure nurses, pharmacy directors, and procurement leaders across hospital systems, clinics, and home care providers to capture firsthand perspectives on therapeutic choice, initiation pathways, and adherence challenges. These frontline insights are complemented by secondary research drawing on peer-reviewed clinical literature, regulatory guidance, and publicly available health system reports to contextualize clinical efficacy, safety, and guideline evolution.

Analytical methods include cross-sectional synthesis of therapeutic classes and care pathways, phenotype-specific clinical mapping for preserved and reduced ejection fraction populations, and scenario analysis to evaluate operational responses to supply-chain variables such as tariff changes. Mode-of-administration and distribution channel dynamics are assessed through case studies and supply-chain mapping exercises that highlight constraints and enablers across hospital pharmacies, retail pharmacies, and online fulfillment channels. Regional analysis integrates regulatory and reimbursement considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific to identify practical implications for adoption.

Throughout, findings have been triangulated across sources to ensure internal consistency and practical relevance. Limitations are acknowledged where public data are sparse or where rapidly evolving clinical evidence may alter therapeutic positioning, and recommendations emphasize adaptable strategies that can be updated as new clinical and operational data emerge.

Consolidated synthesis of clinical, operational, and regional themes underscoring pragmatic pathways to convert therapeutic advances into sustained patient benefit

In summary, the heart failure therapeutics landscape is characterized by substantive clinical evolution and operational complexity. Therapeutic differentiation now extends beyond traditional hemodynamic targets to include agents that deliver renal and metabolic benefits, necessitating more nuanced clinical decision pathways that account for phenotype, acuity, and comorbidity. These scientific advances intersect with shifting care delivery models, where clinics, hospitals, and home care settings each play distinct roles in initiation, titration, and long-term management.

At the same time, distribution and procurement dynamics-shaped by offline hospital and retail pharmacy practices as well as growing online fulfillment-require coordinated strategies to maintain access and ensure continuity of care. Tariff and supply-chain pressures underscore the need for diversified sourcing and tighter alignment between clinical, procurement, and reimbursement stakeholders. Regional variation across the Americas, Europe, Middle East & Africa, and Asia-Pacific further highlights the importance of locally tailored evidence and pricing strategies.

Ultimately, stakeholders who integrate clinical differentiation with operational rigor-aligning evidence generation, supply resilience, and payer engagement-will be best positioned to translate therapeutic advances into measurable improvements in patient outcomes. The path forward emphasizes pragmatism: targeted investments in evidence, partnerships across care settings, and proactive supply-chain management will convert potential into sustained clinical benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Heart Failure Therapeutics Market, by Drug Class

  • 8.1. Ace Inhibitors
  • 8.2. Arbs
  • 8.3. Beta Blockers
  • 8.4. Diuretics
  • 8.5. Mras
  • 8.6. SGLT2 Inhibitors

9. Heart Failure Therapeutics Market, by Heart Failure Type

  • 9.1. Preserved Ejection Fraction
    • 9.1.1. Acute
    • 9.1.2. Chronic
  • 9.2. Reduced Ejection Fraction
    • 9.2.1. Acute
    • 9.2.2. Chronic

10. Heart Failure Therapeutics Market, by Mode Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Heart Failure Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care Settings
  • 11.3. Hospitals

12. Heart Failure Therapeutics Market, by Distribution Channel

  • 12.1. Offline
    • 12.1.1. Hospital Pharmacies
    • 12.1.2. Retail Pharmacies
  • 12.2. Online

13. Heart Failure Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Heart Failure Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Heart Failure Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Heart Failure Therapeutics Market

17. China Heart Failure Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Abiomed, Inc.
  • 18.7. Amgen Inc.
  • 18.8. AstraZeneca PLC
  • 18.9. Bayer AG
  • 18.10. Boehringer Ingelheim International GmbH
  • 18.11. Boston Scientific Corporation
  • 18.12. Bristol-Myers Squibb Company
  • 18.13. Cytokinetics, Inc.
  • 18.14. Edwards Lifesciences Corporation
  • 18.15. Eli Lilly and Company
  • 18.16. GlaxoSmithKline plc
  • 18.17. Johnson & Johnson
  • 18.18. Les Laboratoires Servier
  • 18.19. Medtronic plc
  • 18.20. Merck & Co., Inc.
  • 18.21. Novartis AG
  • 18.22. Pfizer Inc.
  • 18.23. Sanofi S.A.
  • 18.24. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 160. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 196. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)